Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Terminated 5Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × plitidepsin × Clear all
NCT01102426 2020-11-10

ADMYRE

PharmaMar

Phase 3 Completed
255 enrolled 32 charts
Plasma cell

Multiple Myeloma

NCT02100657 2020-10-12

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

PharmaMar

Phase 1 Completed
39 enrolled 30 charts
Plasma cell

Multiple Myeloma

NCT00884286 2018-04-25

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

PharmaMar

Phase 2 Completed
67 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT00229203 2009-12-24

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

PharmaMar

Phase 2 Completed
51 enrolled 10 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡